Kris Leung Kei Siu, Ph.D.
Division of Infectious Diseases
EDUCATIONPh.D., Clinical Microbiology, University of Hong Kong, Hong Kong
B.Sc., Biology, University of Winnipeg, Canada
PROFESSIONAL EXPERIENCES- Assistant Investigator, Associate Investigator, Investigator, Division of Clinical Research, National Health Research Institutes, Taiwan
- Chartered Biologist (CBiol.) and Member (MIBiol) of Royal Institute of Biology, UK
- Member, the American Society of Microbiology, USA
- Registered Medical Laboratory Technologists of the Medical Laboratory Technologists Board, Hong Kong
- Fellow (FIBMS) of Institute of Biomedical Science, UK
RESEARCH INTERESTSTherapeutic control of antibiotic resistance bacteria has been a major clinical problem for the past 40 years. Bacteria are most often resistant to antibiotics as a result of acquisition of resistant gene or gene mutation. Studies showed that newly developed antibiotics will shortly fail to be active against the bacteria because of the emergence of resistance. Some resistant bacteria have been found to exist even before the antibiotic was developed. The inappropriate use of new extended spectrum antibiotics complicated the problem even more. Since resistance is a largely unavoidable consequence of widespread utilization, it would seem prudent to ensure that the use of drugs is selective by exercising prudent judgment and not excessive. Conspicuously, the actual prevalence of resistance should be monitored continuously year by year. Direct extrapolation of study results from other geographic areas should be avoided since the local prevalence of resistance is unlikely to be identical to that reported elsewhere. If such information is available, it can help to design strategies for maximizing the therapeutic usefulness of drugs and minimizing the emergence of resistance. Although we have yet to reach such a worst-case scenario in antibiotics resistance, we cannot just simply ignore the problem or wait until it is uncontrollable. If we ignore, single drug therapy will simply become obsolete.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSTo study of bacterial infectious disease and antibiotic resistance in Taiwan, several approaches have been adopted in Dr. Siu's laboratory. As given in his recent publications, Dr. Siu has refined the routine susceptibility method with regard to their performance and result interpretation, taking into account of the necessity for prudent use of antibiotics and the evolution of ESBL resistance. In addition, the results obtained in the study of pneumoccocus infection highlighted that most of the currently available antibiotics for pneumoccocus infection especially in children are inactive. Thus, accurate detection of resistance can help to reduce the excessive use of antibiotics and treatment failure. Although the recently developed quinolones seems to be a good choice as an alternative for drugs resistant pneumoccocus infection, the first identification of gryA mutated resistant isolates could not be simply excluded. In the future, Dr. Siu will continue to study the mechanism of antibiotic resistance as well as the pathogenesis of specific bacterial infection in Taiwan. It is hoped that Dr. Siu's research results will help to maximize the activity of antibiotic usage and minimize the emergence of resistance.
- Jung-Chung Lin**, L. K. Siu**, Chang-Phone Fung, Hsiao-Hui Tsou, Jaang-Jiun Wang, Chiung-Tong Chen, Shu-Chuan Wang, and Feng-Yee Chang*. Impaired Phagocytosis of Capsular Serotypes K1 or K2 Klebsiella pneumoniae in Type 2 Diabetes Mellitus patients with Poor-Glycemic Control. J Clin Endocr Metab. 91(8):3084-7, 2006.
- Kuo-Ming Yeh, Feng-Yee Chang, Chang-Phone Fung, Jung-Chung Lin, L. K. Siu*. MagA is not a specific gene for Klebsiella pneumoniae liver abscess but a part of the capsular polysaccharide (CPS) gene cluster for Klebsiella pneumoniae serotype K1. J Med Microbiol. 55: 803-804, 2006.
- Ling Ma, Jimena Alba, Feng-Yee Chang, Masaji Ishiguro, Keizo Yamaguchi, L. K. Siu, and Yoshikazu Ishii. A Novel SHV-Derived Extended-Spectrum b-Lactamase (SHV-57) That Confers Resistance to Ceftazidime But Not Cefazolin. Antimicrob. Agents Chemother. 49(2):600-5, 2005.
- Chih-Chien Wang, Wen-Tsung Lo, Mong-Ling Chu, and L. K. Siu. Epidemiological Typing of Community-Acquired Methicillin-Resistant Staphylococcus aureus Isolates from Children in Taiwan. Clin Infect Dis. 15;39(4):481-7, 2004.
- J-Y. Chen, Chang-Phone Fung, Feng-Yee Chang, Li-Yueh Huang, Jen-Chang Chang and L. K. Siu.* Mutations of the rpoB gene in rifampicin-resistant Streptococcus pneumoniae in Taiwan. J Antimicrob. Chemother 53(2):375-8, 2004.
(* = Corresponding Author; ** = Contributed equally)